The Impact of Neoadjuvant Chemotherapy and Adjuvant Chemotherapy on NSCLC Supported by Evidence-based Medicine

Qingfeng ZHENG,Yuzhao WANG,Sainan ZHU,Yiqiang LIU,Shaolei LI,Nan WU,Jinfeng CHEN,Lijian ZHANG,Yue YANG

DOI: https://doi.org/10.3969/j.issn.1000-8179.2011.04.015

2011-01-01

Chinese Journal of Clinical Oncology

Abstract:Objective:To investigate the effect of neoadjuvant chemotherapy and adjuvant chemotherapy on NSCLC on the basis of evidence-based medicine.Methods:From January 2004 to August 2009,there were 191 cases who had received platinum-based two-drug combination chemotherapy.The group distribution characteristics of these cases were analyzed and the effect of chemotherapy was observed by T staging assessment and R0 resection ratio.Overall survival (OS),the median survival time (MST) and disease free survival (DFS) were analyzed with SPSS 16.0.These research data were compared with previous data of high-level evidence.Results: Of the 191 cases,37 (19.37%) cases were treated with neoadjuvant chemotherapy (NCT) followed by surgery (stage ⅢB accounted for 24.3%,Ⅲ A 74.1%) and 154 cases accepted surgery followed by adjuvant chemotherapy (ACT).In the NCT plus surgery group,the response rate (RR=CR+PR) was 70.3%,pathological complete response (pCR) was 5.4%,the MST was 14.6 months (arranged 6.18 to 23.01),the 1-year survival was 86.0%,and the 3-year survival was 53.9%.The 1-year DFS was 62.1%,and the 3-year DFS was 23.4%.In the surgery plus ACT group,the MST was 25.9 months (19.03-32.77),the 1-year survival was 93.3%,and the 3-year survival was 73.8%.The 1-year DFS was 71.0%,and the 3-year DFS was 34.0%.Conclusion:According to high-level evidence, adjuvant chemotherapy can be better treatment option for the majority of NSCLC cases.Patients of stage Ⅱ-ⅢA and some resectable patients of stage ⅢB can get most benefits from neoadjuvant chemotherapy and adjuvant chemotherapy.